Human respiratory syncytial virus (RSV) is one of the most common viruses to infect children worldwide and now increasingly is recognized as an important pathogen in adults, especially the elderly. Globally each year, there are over 33m episodes of RSV-associated acute lower respiratory infection in children younger than 5 yrs of age resulting at least 3.2m hospital admissions and 59,600 in hospital deaths (2015 estimation, Shi T et al., 2017). In children below 5 yrs, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. There is no specific treatment for RSV infection and for those children who require hospitalization (~1-2% of healthy), supportive therapy is still the mainstay of care.
Palivizumab (anti-RSV monoclonal, Synagis�) has been FDA approved since 1998 for the prophylaxis of specific subsets of premature infants.
Despite serious setbacks in the late 1960s with a formalin-inactivated RSV vaccine, the RSV vaccine development field is now one of the most active in the industry.
Major companies such as Pfizer, GSK Biologicals, Janssen NV and smaller biotech�s e.g. Novavax have a range of vaccine approaches in active clinical development targeting all the recognized target populations.
Newer long-acting monoclonal antibodies such as MEDI8897 (MedImmune) are also being pursued.
This MarketVIEW product is a comprehensive Executive Presentation (~225 slides, .pdf) and 2 MS-Excel forecast models which investigate the scenario-based interplay and commercial potential of four RSV vaccine profiles
in all relevant target groups (e.g. maternal, infant, adult �at risk� and elderly) to 2035. 52 countries and sub-regions are included in the model with expected public and private sector vaccination being indicated.
A methodology has been created whereby country specific roll-out is forecasted according to specific local factors and RSV transmission patterns which may in turn influence RSV program adoption.
The report contains a thorough review of current disease background/epidemiology/CE and vaccinology with an emphasis on structural-based antigen engineering.
An analysis of the R&D competitive environment (including long acting mAbs) is also provided with an in-depth discussion of the latest ResVax (Novavax) PREPARE Phase III data.
This product is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV vaccine opportunity.
THIS PRODUCT IS A SUMMARY PRESENTATION (~225 slides, .pdf) + 2 scenario-based MS Excel Workbook(s) Photo credit: Picsea @picsea